Clinical Trials

Pancreatic Neoplasms

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05924997 2024-02-21

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

52 enrolled

Carcinoma, Hepatocellular

NCT06235164 2024-01-31

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Unknown

585 enrolled

Locally Advanced Gastric Cancer

NCT05062837 2024-01-23

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Phase 2/3 Unknown

62 enrolled

Carcinoma, Hepatocellular

NCT05031949 2023-12-19

CCGLC-003

Phase 1 Unknown

20 enrolled

Carcinoma, Hepatocellular

NCT04559607 2023-12-18

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

188 enrolled

Carcinoma, Hepatocellular

NCT04930315 2023-06-13

CAPT

78 enrolled

Carcinoma, Hepatocellular

NCT04609176 2023-04-21

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

64 enrolled

Stomach Neoplasms

NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

50 enrolled

Cholangiocarcinoma

NCT04443309 2023-03-29

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

53 enrolled

Carcinoma, Hepatocellular

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

20 enrolled

Carcinoma, Hepatocellular

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT05697237 2023-01-25

Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

60 enrolled

Cholangiocarcinoma

NCT05669807 2023-01-03

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

184 enrolled

Second Line Treatment of Gastric Cancer

NCT05650216 2022-12-14

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT05637268 2022-12-05

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

23 enrolled

Esophageal Neoplasms

NCT05545436 2022-09-22

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

34 enrolled

Locally Advanced Gastric Cancer

NCT05476380 2022-07-27

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

39 enrolled

Esophageal Neoplasms

NCT04866862 2022-07-25

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

32 enrolled

Colorectal Neoplasms

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05441254 2022-07-08

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

33 enrolled

Stage IV Gastric Cancer With Metastasis

NCT05019534 2022-05-19

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Phase 1 Unknown

12 enrolled

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

NCT04487704 2022-04-29

Camrelizumab Utilization on Patients With Advanced Liver Cancer

1,000 enrolled

Advanced Hepatocellular Carcinoma

NCT05339581 2022-04-27

iPLENTY-pvtt

78 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

68 enrolled

Metastatic Gastric Adenocarcinoma

NCT04675866 2022-04-15

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

46 enrolled

Advanced Gastric Adenocarcinoma

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

15 enrolled

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT05322499 2022-04-11

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

176 enrolled

Carcinoma, Hepatocellular

NCT05225844 2022-02-07

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

150 enrolled

Gastrointestinal Neoplasms

NCT04390945 2022-02-03

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

62 enrolled

Esophageal Neoplasms

NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

77 enrolled

Intestinal Neoplasms, Colorectal Neoplasms

NCT05183958 2022-01-11

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

118 enrolled

Esophageal Neoplasms

NCT05171309 2021-12-28

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

35 enrolled

Carcinoma, Hepatocellular

NCT04506138 2021-12-14

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

46 enrolled

Esophageal Squamous Cell Carcinoma

NCT04286958 2021-12-10

ESCC

40 enrolled

Esophageal Neoplasms

NCT05135364 2021-11-26

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

48 enrolled

Carcinoma, Hepatocellular

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

65 enrolled

Stomach Neoplasms

NCT05095636 2021-10-27

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

102 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT04006821 2021-09-30

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

30 enrolled

Stomach Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Phase 3 Unknown

234 enrolled

Esophageal Neoplasms

NCT04932187 2021-09-17

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Phase 1 Unknown

20 enrolled

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

NCT04426955 2021-09-16

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Phase 3 Unknown

396 enrolled

Esophageal Neoplasms

NCT04724226 2021-09-05

C-couple

34 enrolled

Carcinoma, Hepatocellular

NCT04654403 2021-08-23

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

337 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04984018 2021-07-30

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

73 enrolled

Esophageal Squamous Cell Carcinoma

NCT03766178 2021-07-07

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

35 enrolled